Skip to main content
Caplight Logo









Ukko

Ukko

Private
Boston, MassachusettsHealthcare & Life Scienceshttps://www.ukko.us/

Last Round

Series C

Jan 8, 2026

Total Funding Raised

$92.7M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Ukko is a biotechnology company that develops immunity-boosting proteins and novel immunotherapies aimed at treating food allergies and immune-mediated conditions.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Medical AI

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

computational biologyprotein designfood allergy treatmenthypoallergenic ingredientsbiotechdrug discoveryallergen engineeringfood techAI drug discoverytherapeutic candidatesepitope mappingprotein engineeringimmunologyfood safetybiopharma

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Ukko Comparables

Compare Ukko with similar companies based on industry and business-model similarity.

Ukko comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
IgGenix
75%
Nestlé
69%
Biolojic Design
65%

Ukko Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CJan 8, 2026
Series BJan 27, 2021
Series AJul 24, 2017

Key People

Founding team and executive leadership

Anat Binur

Co-founder And CEO

Founding Team

Moshe Ben-David

Chief Technology Officer

Executive Team

Matt Ottmer

Chief Operating Officer

Executive Team

Ukko Investors

Notable investors and investment history

Ukko investors
InvestorRounds
Fall Line CapitalSeries C, Series B
Israel Biotech FundSeries C
Skyviews Life ScienceSeries B
TIME VenturesSeries B
Khosla VenturesSeries C, Series A, Series B
Innovation EndeavorsSeries A, Series B
PeakBridgeSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 26, 2026

    Grew 17% QoQ, from 58 to 68 employees.

  • May 17, 2026

    Monthly visitors grew 108% MoM, reaching 2.5K.

Ukko Filings

Explore SEC and related filing metadata, where available.

Ukko filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Ukko's valuation, stock price, and market status.

Is Ukko a public or private company?

Ukko is a private company.

What is the current stock price of Ukko?

Ukko is a private company with no public stock price. No recent secondary market data is available.

How much is Ukko worth (valuation)?

Valuation information for Ukko is not publicly available.

Can I buy Ukko stock?

Ukko shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Ukko's last funding round?

Ukko's most recent funding round was Series B on January 27, 2021.

Who are the main investors in Ukko?

Key investors in Ukko include Leaps by Bayer.

Will Ukko IPO soon?

No public IPO plans have been announced for Ukko.

How can I track Ukko secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Ukko's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersBoston, Massachusetts
Employee Range27
Year Founded2016
Last FundingJan 8, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?